Zealand Pharma Financials
| ZEAL Stock | DKK 626.00 15.00 2.45% |
Zealand |
Understanding current and past Zealand Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Zealand Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Zealand Pharma's assets may result in an increase in income on the income statement.
The data published in Zealand Pharma's official financial statements usually reflect Zealand Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Zealand Pharma AS. For example, before you start analyzing numbers published by Zealand accountants, it's critical to develop an understanding of what Zealand Pharma's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Zealand Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zealand Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Zealand Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Zealand Pharma AS. Please utilize our Beneish M Score to check the likelihood of Zealand Pharma's management manipulating its earnings.
Zealand Pharma Stock Summary
Zealand Pharma competes with Ambu AS, DSV Panalpina, Bavarian Nordic, GN Store, and FLSmidth. Zealand Pharma AS, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 360 people.| Foreign Associate | USA |
| Instrument | Denmark Stock View All |
| Exchange | Copenhagen Exchange |
| ISIN | DK0060257814 |
| Business Address | Sydmarken 11, Copenhagen, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | NYSE Composite |
| Website | www.zealandpharma.com |
| Phone | 45 88 77 36 00 |
| Currency | DKK - Danish Krone |
You should never invest in Zealand Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Zealand Stock, because this is throwing your money away. Analyzing the key information contained in Zealand Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Zealand Pharma Key Financial Ratios
Generally speaking, Zealand Pharma's financial ratios allow both analysts and investors to convert raw data from Zealand Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Zealand Pharma over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Zealand Pharma AS reports annually and quarterly.| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 | |||
| Target Price | 243.75 |
Zealand Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Zealand Pharma's current stock value. Our valuation model uses many indicators to compare Zealand Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zealand Pharma competition to find correlations between indicators driving Zealand Pharma's intrinsic value. More Info.Zealand Pharma AS is rated first in return on equity category among related companies. It is rated first in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Zealand Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Zealand Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Zealand Pharma's earnings, one of the primary drivers of an investment's value.Zealand Pharma AS Systematic Risk
Zealand Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Zealand Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Zealand Pharma AS correlated with the market. If Beta is less than 0 Zealand Pharma generally moves in the opposite direction as compared to the market. If Zealand Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Zealand Pharma AS is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Zealand Pharma is generally in the same direction as the market. If Beta > 1 Zealand Pharma moves generally in the same direction as, but more than the movement of the benchmark.
About Zealand Pharma Financials
What exactly are Zealand Pharma Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Zealand Pharma's income statement, its balance sheet, and the statement of cash flows. Potential Zealand Pharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Zealand Pharma investors may use each financial statement separately, they are all related. The changes in Zealand Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Zealand Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Zealand Pharma Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Zealand Pharma is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Zealand has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Zealand Pharma's financials are consistent with your investment objective using the following steps:- Review Zealand Pharma's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Zealand Pharma's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Zealand Pharma's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Zealand Pharma's stock is overvalued or undervalued.
Zealand Pharma April 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Zealand Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Zealand Pharma AS. We use our internally-developed statistical techniques to arrive at the intrinsic value of Zealand Pharma AS based on widely used predictive technical indicators. In general, we focus on analyzing Zealand Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Zealand Pharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.5 | |||
| Information Ratio | 0.095 | |||
| Maximum Drawdown | 42.53 | |||
| Value At Risk | (4.39) | |||
| Potential Upside | 5.07 |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zealand Pharma AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Zealand Stock analysis
When running Zealand Pharma's price analysis, check to measure Zealand Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zealand Pharma is operating at the current time. Most of Zealand Pharma's value examination focuses on studying past and present price action to predict the probability of Zealand Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zealand Pharma's price. Additionally, you may evaluate how the addition of Zealand Pharma to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |